No abstract

No abstract

No abstract

includes cardiogenic shock in 18 patients (38%) and postcardiotomy cardiogenic shock in 29 patients (62%). Thirty-eight patients of the 47 total patients (80%) were supported withImpella 5.0/LD and with Impella 2.5 for the remaining 9 (19%) patients. . The 30-day survival rate was 75% (35/47) and of those 97% (34/35) recovered their native heart function and 1 (3%) was bridged to long term ventricular assist device Complications occurred in 14 (30%) patients and consisted of device malfunction (11%), high purge pressures (6%), catheter fracture (2%), and groin hematoma (2%). Conclusions: The outcomes from our study were very favorable; myocardial recovery was accomplished in the majority of the patients with acceptable complication rate in these critically ill patients. These benefits encourage the use of a less invasive circulatory support with Impella in the setting of cardiogenic shock.

No abstract